1. Introduction {#sec1}
===============

Recruitment of research participants into pediatric clinical trials is a major issue that investigators and sponsors have to tackle. The pool of eligible children is often small, and the threshold for gaining consent is often higher and more complex because parents have to make decisions about trial participation on behalf of their child.

Nevertheless, recruitment of patients into clinical trials is crucial for reaching target sample size and being able to test the trial hypotheses with adequate power. Only with a sufficient number of participants it is possible to provide evidence-based results for the development of therapies and medical strategies for several diseases like type 1 diabetes in children.

While there is quite some insight into recruitment practices and problems in adults \[[@bib1], [@bib2], [@bib3], [@bib4]\], especially for severe diseases like cancer \[[@bib5], [@bib6], [@bib7]\], evidence on successful techniques of increasing recruitment numbers is still sparse \[[@bib8],[@bib9]\].

This is even more true for pediatric trials recruiting infants. Recruitment strategies \[[@bib10]\] and participant characteristics that predict recruitment are rarely reported \[[@bib11]\]. For preventive trials in asymptomatic children the problem of slow recruitment seems to be even more evident \[[@bib12]\] but not much information is available on this topic.

In the Fr1da Insulin Intervention study children with early type 1 diabetes receive oral insulin or placebo for 12 months as a secondary prevention in order to test immune efficacy of oral insulin up to a dose of 67.5 mg. Early type 1 diabetes is characterized by multiple islet autoantibodies. The dose of oral insulin was defined in a preceding pilot study (Pre-Point) that demonstrated that this dose resulted in an immune response with signs of T cell regulation \[[@bib13]\].

Almost all children eligible for the trial will develop symptomatic T1D in the near future \[[@bib14]\]. While T1D is well treatable, it still comes with significant restrictions due to disease-specific problems for children \[[@bib15]\] and their parents \[[@bib16]\]. Despite that recruitment into the trial was slower than expected. Here we cover the difficulties in recruitment of children and their parents for participation in the study.

2. Methods {#sec2}
==========

The first step of the project is a population based screening for early stage type 1 diabetes - the Fr1da study (ethics no.: 70/14) \[[@bib17]\]. Inclusion criteria were:1.The child is between 2 and 5 years old2.The child is living in Bavaria, Germany.

The screening is offered by primary care and has been established in January 2015. It is still ongoing and aiming to include 100,000 children. The concept of the Fr1da study was published by Raab et al. \[[@bib18]\].

In a second step all children participating in the screening and diagnosed with antibodies to glutamic acid decarboxylase (GAD65), to insulin (IAA), autoantibodies to IA-2 (IA2A), or autoantibodies to zink transporter 8 (ZnT8A) are asked to participate in the Fr1da Insulin Intervention trial. Parents were contacted to schedule an appointment for an initial visit.

The Fr1da Insulin Intervention study is a randomized, placebo-controlled, double-blind, mono-center secondary intervention study of high-dose oral insulin to delay or prevent clinical symptomatic type 1 diabetes ([clinicaltrials.gov](http://clinicaltrials.gov){#intref0010} [NCT02620072](ctgov:NCT02620072){#intref0015}).

A child is eligible for the Fr1da Insulin Intervention trial if it:1.is two to 12 years old2.has at least two confirmed positive islet autoantibodies out of GADA, IAA, IA2A, or ZnT8A and time between screening sample collection and randomization did not exceed 90 days.3.has a normal glucose tolerance after an oral glucose tolerance test. Normal glucose tolerance is defined as fasting glucose \<110 mg/dl, and a glucose level 2 h after ingestion of oral glucose \<140 mg/dl, and intermediate glucose levels at 30 min and 60 min and 90 min after ingestion of oral glucose \<200 mg/dl.

Included children are randomized to the insulin or placebo group in a 1:1 ratio. The allocated study capsules are administered for 12 months as powder spotted on food. Children who completed the intervention period and who have not developed type 1 diabetes will be continued to be monitored for at least one year and a maximum of 7 years. Study related burdens are daily administration of insulin powder in food over 12 months and five study visits during the one-year intervention period at the study site in Munich, taking approximately 2.5 h including a physical examination, a saliva sample and a venous blood draw with five sampling times. Additionally, an OGTT is performed and stool is collected every six months. After the intervention period families are asked to visit the study site every six months. During each visit an OGTT will be performed. During the whole observation period families are asked to document adverse events and additional medications.

This manuscript consists of two main analyses:1.Parents of eligible children who did not agree to participate in the trial were called and asked for reasons for their non-participation. The reasons given by the parents were categorized. Percentages, medians and ranges were calculated according to the data type.2.We analyzed sex and age of the child, distance of the family to the study center in Munich and the existence of a first degree family member with type 1 diabetes of all eligible children. To identify if those factors were influencing the participation in the trial we calculated a logistic regression model. From this model we calculated Odds Ratios and the respective 95% confidence limits and the p values of the Wald test.

3. Results {#sec3}
==========

Overall, by January 2018 72,192 children were screened in the context of the Fr1da-study and 146 Fr1da children who were eligible according to the inclusion criteria were invited to participate in the Fr1da Insulin Intervention trial. Of those 77 (53%) were eventually enrolled in the study. Baseline characteristics are described in [Table 1](#tbl1){ref-type="table"}. Neither the age of the child nor sex, distance to the study center or a first degree relative with type 1 diabetes had a significant influence on the decision to participate in the study.Table 1Baseline characteristics of eligible patients and Odds Ratios and p values from the logistic regression model.Table 1AllParticipatingNot participatingOdds ratio (95% CI)P valueN1467769----Median Age in years (Min-Max)4 (2--10)4 (2--10)4 (2--10)1.09 (0.88--1.35)0.4511Male sex, n (%)84 (58)43 (56)41 (59)0.78 (0.39--1.53)0.4633First degree relative with type 1 diabetes, n (%)21 (14)12 (16)9 (13)0.98 (0.36--2.66)0.9685Median distance to study center in km (Min-Max)88 (0--270)68 (0--270)88 (0--270)1.00 (0.99--1)0.0699

The parents who declined trial participation for their children were asked for the main reason on the phone. Of 69 families who did not participate in the study 61 responded to the call ([Fig. 1](#fig1){ref-type="fig"}). [Table 2](#tbl2){ref-type="table"} summarizes the reasons given by the parents for not participating in the study.Fig. 1Flowchart of the transfer of children from the Fr1da screening to the Fr1da Insulin Intervention Trial.Fig. 1Table 2Recruitment of participants for the Fr1da Insulin Intervention study.Table 2reason for non-participationtotal number of families (N = 61)percentage (%)time restriction2236venous blood draw1830without specification711still undecided58placebo47no need to participate47contact undesirable12

Most parents stated time issues as their main reason for refusal (36%). Regarding this, families state long travelling distance especially if they have more children. Consequentially, only 19% of the families from Munich state time as the main reason for non-participation while 42% of families do so who need to travel longer. The second most frequent reason for refusal was the venous blood draw (30%). 11% of parents did not specify their decision. 8% of the parents were still undecided whether they should agree to participate in the study. These parents will be contacted again. 7% of the parents were not convinced of the concept of the study and stated no need to participate in an intervention trial to prevent type 1 diabetes. The same number defined the possibility to receive placebo as main reason for refusal. Just one family did not want to be contacted by the study team.

4. Discussion {#sec4}
=============

Participants of randomized clinical trials (RCTs), including those assigned to placebo, have outcomes similar to or better than those of eligible non-participants. In the case of type 1 diabetes, participants may have lower complication rates at disease onset with a significant reduction in the frequency of diabetic ketoacidosis, a better long term metabolic control, and a reduction in hospitalization rates compared to children outside of RCTs \[[@bib19]\].

Continuous monitoring of the blood glucose as part of the Fr1da Insulin Intervention study prevents undiscovered changes in glucose metabolism. Medical attendance and training by the study team provides the families with information about the disease and facilitates coping with type 1 diabetes, especially for families with no experience concerning the disease. Taken together participation in the Fr1da Insulin Intervention study might result in an improved medical care \[[@bib20], [@bib21], [@bib22]\]. Also, the intervention with high-dose oral insulin was shown to be safe in the Pre-POINT study \[[@bib12]\], in the Pre-POINT Early study ([clinicaltrials.gov](http://clinicaltrials.gov){#intref0020} [NCT02547519](ctgov:NCT02547519){#intref0025}) and in the TrialNet TN20 trial ([clinicaltrials.gov](http://clinicaltrials.gov){#intref0030} [NCT02580877](ctgov:NCT02580877){#intref0035}) using an even higher dose (ADA oral presentation 2017). Thus it seems surprising that almost half of the parents of eligible children who were informed of the study did not enroll their children.

Neither age nor sex of the child nor a relative with type 1 diabetes influenced parental decision on trial participation. Also the use of placebo in the control group was not a major reason for non-participation as it was reported in other research \[[@bib23]\]. The two main reasons for non-participation were time restrictions and the venous blood draw. Time restriction is also mirrored in the distance to study center. Families enrolling in the trial lived closer to the study site than families refusing to enroll. Especially families with more than one child were reluctant to enroll if they needed to travel longer and study participation would use up a lot of time, also because older children miss school and have to catch up missed material.

Non-enrolling families stating as their main reason the venous blood-draw often reported either negative experiences with previous venous blood draws or a general reluctance regarding such interventions. As soon as the induction of immune efficacy and immune regulation using oral insulin at a dose of 67.5 mg has been demonstrated in this secondary prevention study, future studies may be able to replace venous blood draws by a capillary blood test thereby facilitating easier recruitment to this type of studies.

A limitation of our work is that we unfortunately do not have more information on families to explore reasons for non-participation in more detail such as socioeconomic status, parental education or length of the initial information visit that were shown to be relevant for participation in other studies \[[@bib11],[@bib24]\].

A French review on the topic of recruitment in pediatric clinical trials reports much lower rates of non-participation (median refusal rate 12.5%) \[[@bib24]\] than we saw in the Fr1da insulin intervention trial (47%). This might in part be due to the structure of the study but could also reflect some pre-selection occurring in other trials. Usually there are two barriers to trial participation: which eligible families are approached by the doctor and do these families agree to enroll. In our scenario with a population based screening without any preselection as a prerequisite to trial inclusion we see that efforts to inform families better about the benefits and lower the burden of clinical trials could result in much higher rates of study participation.

5. Conclusions {#sec5}
==============

This project shows the lack of information on the reasons why families decline or agree to enroll their children into clinical trials and points out why it is important to identify factors that impede trial participation in children. The factors identified in this study were mainly time restrictions and the venous blood draw. These factors may be taken into account for future designs of trials in pediatric population, or be taken up in awareness and education programs to better inform families of the necessity and impact of certain trial elements. To maximize the benefit for participating children and the scientific community the benefits for parents and their children have to be highlighted: currently there is no known treatment to prevent or delay type 1 diabetes in children or adults but study participants will have the opportunity to access a promising treatment to delay or even avoid clinical symptomatic diabetes \[[@bib25]\].

Declarations of conflicts of interest {#sec6}
=====================================

The authors declare that they do not have any conflicts of interest.

Trial registration number and trial register {#sec7}
============================================

Fr1da study (approval by a local ethics committee in Germany (Ethikkommission der Fakultät für Medizin der Technischen Universität München, reference number: 70/14).

Fr1da-Insulin-Intervention Study (EudraCT-no.: 2015-003028-30; Clinicaltrials. gov Identifier: NCT02620072; approval by a local ethics committee in Germany (Ethikkommission der Fakultät für Medizin der Technischen Universität München, reference number: 420/15Af)).

Funding/grant support {#sec8}
=====================

The Fr1da study is supported by grants from the LifeScience-Stiftung, JDRF (1-SRA-2014-310-M-R), the Bavarian State Ministry of Health and Care (Gesund.Leben.Bayern, LP00228), Deutsche Diabetes-Stiftung, Landesverband Bayern der Betriebskrankenkassen, B. Braun-Stiftung (BBST-D-15-00016) and Deutsche Diabetes-Hilfe.

The Fr1da-Insulin-Intervention Study is supported by grants from the Leona M. & Harry B. Helmsley Charitable Trust (Grant \#2016 PG-T1D020). Insulin crystals were provided by Lilly Pharmaceuticals.

Appendix A. Supplementary data {#appsec1}
==============================

The following is the supplementary data related to this article:Data ProfileData Profile

Supplementary data related to this article can be found at [https://doi.org/10.1016/j.conctc.2018.08.004](10.1016/j.conctc.2018.08.004){#intref0040}.
